A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

NCT00456521 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

793

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day
DRUG: Placebo
BEHAVIORAL: Intensive group lifestyle modification counseling

Sponsor

Orexigen Therapeutics, Inc